US 12023348
EGR1 targeting molecules for the treatment of inflammatory and hyperproliferative conditions
granted A61KA61K31/122A61K31/137
Quick answer
US patent 12023348 (EGR1 targeting molecules for the treatment of inflammatory and hyperproliferative conditions) held by The Medical Research, Infrastructure and Health Services Fund of the Tel-Aviv Medical Center expires Mon Jun 27 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The Medical Research, Infrastructure and Health Services Fund of the Tel-Aviv Medical Center
- Grant date
- Tue Jul 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jun 27 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 11
- CPC classes
- A61K, A61K31/122, A61K31/137, A61K31/167, A61K31/277